Cargando…

Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma

Purpose. Fluorescein angiographic studies revealed prolonged arteriovenous passage (AVP) times and increased fluorescein filling defects in normal tension glaucoma (NTG) compared to healthy controls. The purpose of this study was to correlate baseline AVP and fluorescein filling defects with visual...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Eva Charlotte, Arend, Kay Oliver, Bienert, Marion, Remky, Andreas, Plange, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824313/
https://www.ncbi.nlm.nih.gov/pubmed/24282387
http://dx.doi.org/10.1155/2013/726912
_version_ 1782290691210084352
author Koch, Eva Charlotte
Arend, Kay Oliver
Bienert, Marion
Remky, Andreas
Plange, Niklas
author_facet Koch, Eva Charlotte
Arend, Kay Oliver
Bienert, Marion
Remky, Andreas
Plange, Niklas
author_sort Koch, Eva Charlotte
collection PubMed
description Purpose. Fluorescein angiographic studies revealed prolonged arteriovenous passage (AVP) times and increased fluorescein filling defects in normal tension glaucoma (NTG) compared to healthy controls. The purpose of this study was to correlate baseline AVP and fluorescein filling defects with visual field progression in patients with NTG. Patients and Methods. Patients with a follow-up period of at least 3 years and at least 4 visual field examinations were included in this retrospective study. Fluorescein angiography was performed at baseline using a confocal scanning laser ophthalmoscope (SLO, Rodenstock Instr.); fluorescein filling defects and AVP were measured by digital image analysis and dye dilution curves (25 Hz). Visual field progression was evaluated using regression analysis of the MD (Humphrey-Zeiss, SITA-24-2, MD progression per year (dB/year)). 72 patients with NTG were included, 44 patients in study 1 (fluorescein filling defects) and 28 patients in study 2 (AVP). Results. In study 1 (mean follow-up 6.6 ± 1.9 years, 10 ± 5 visual field tests), MD progression per year (−0.51 ± 0.59 dB/year) was significantly correlated to the age (P = 0.04, r = -0.29) but not to fluorescein filling defects, IOP, or MD at baseline. In study 2 (mean follow-up 6.6 ± 2.2 years, 10 ± 5 visual field tests), MD progression per year (−0.45 ± 0.51 dB/year) was significantly correlated to AVP (P = 0.03, r = 0.39) but not to age, IOP, or MD at baseline. Conclusion. Longer AVP times at baseline are correlated to visual field progression in NTG. Impaired retinal blood flow seems to be an important factor for glaucoma progression.
format Online
Article
Text
id pubmed-3824313
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38243132013-11-26 Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma Koch, Eva Charlotte Arend, Kay Oliver Bienert, Marion Remky, Andreas Plange, Niklas ScientificWorldJournal Clinical Study Purpose. Fluorescein angiographic studies revealed prolonged arteriovenous passage (AVP) times and increased fluorescein filling defects in normal tension glaucoma (NTG) compared to healthy controls. The purpose of this study was to correlate baseline AVP and fluorescein filling defects with visual field progression in patients with NTG. Patients and Methods. Patients with a follow-up period of at least 3 years and at least 4 visual field examinations were included in this retrospective study. Fluorescein angiography was performed at baseline using a confocal scanning laser ophthalmoscope (SLO, Rodenstock Instr.); fluorescein filling defects and AVP were measured by digital image analysis and dye dilution curves (25 Hz). Visual field progression was evaluated using regression analysis of the MD (Humphrey-Zeiss, SITA-24-2, MD progression per year (dB/year)). 72 patients with NTG were included, 44 patients in study 1 (fluorescein filling defects) and 28 patients in study 2 (AVP). Results. In study 1 (mean follow-up 6.6 ± 1.9 years, 10 ± 5 visual field tests), MD progression per year (−0.51 ± 0.59 dB/year) was significantly correlated to the age (P = 0.04, r = -0.29) but not to fluorescein filling defects, IOP, or MD at baseline. In study 2 (mean follow-up 6.6 ± 2.2 years, 10 ± 5 visual field tests), MD progression per year (−0.45 ± 0.51 dB/year) was significantly correlated to AVP (P = 0.03, r = 0.39) but not to age, IOP, or MD at baseline. Conclusion. Longer AVP times at baseline are correlated to visual field progression in NTG. Impaired retinal blood flow seems to be an important factor for glaucoma progression. Hindawi Publishing Corporation 2013-10-24 /pmc/articles/PMC3824313/ /pubmed/24282387 http://dx.doi.org/10.1155/2013/726912 Text en Copyright © 2013 Eva Charlotte Koch et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Koch, Eva Charlotte
Arend, Kay Oliver
Bienert, Marion
Remky, Andreas
Plange, Niklas
Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
title Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
title_full Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
title_fullStr Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
title_full_unstemmed Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
title_short Arteriovenous Passage Times and Visual Field Progression in Normal Tension Glaucoma
title_sort arteriovenous passage times and visual field progression in normal tension glaucoma
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824313/
https://www.ncbi.nlm.nih.gov/pubmed/24282387
http://dx.doi.org/10.1155/2013/726912
work_keys_str_mv AT kochevacharlotte arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma
AT arendkayoliver arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma
AT bienertmarion arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma
AT remkyandreas arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma
AT plangeniklas arteriovenouspassagetimesandvisualfieldprogressioninnormaltensionglaucoma